SCHEMBL7077784

SCHEMBL7077784

Cc1ccnc(C(=O)CC(=O)c2cc(-n3cccc3)cc(-n3cccc3)c2C)c1

nearest known ligand 0.37

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
LMNA P02545 1/20 0.35
RAB9A P51151 3/20 0.35
NPC1 O15118 2/20 0.35
CTSA P10619 2/20 0.34
L3MBTL1 Q9Y468 3/20 0.34
POLB P06746 2/20 0.34
HTT P42858 1/20 0.34
TDP1 Q9NUW8 1/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
ALDH1A1 P00352 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7078633 0.82 KMT2A (0.43) LMNAMEN1KMT2AALDH1A1
SCHEMBL7079537 0.70 CTNNB1 (0.41) LMNAKMT2A
SCHEMBL15926105 0.68 CTSA (0.43) KDM4ERAB9ANPC1CTSAL3MBTL1
SCHEMBL7077781 0.68 HDAC1 (0.38) RAB9ANPC1CTSAMEN1KMT2A
SCHEMBL7082139 0.67 WNT3A (0.39) RAB9ANPC1CTSAMEN1KMT2A
SCHEMBL7083036 0.67 CYP19A1 (0.41) LMNAHTTMEN1KMT2AALDH1A1
SCHEMBL31312593 0.66 ALDH1A1 (0.42) KDM4ELMNARAB9ANPC1CTSA
SCHEMBL7081705 0.66 HTT (0.48) KDM4ERAB9ANPC1HTTTDP1
SCHEMBL2643034 0.65 UHRF1 (0.43) KDM4ELMNARAB9ANPC1CTSA
SCHEMBL30885027 0.65 UHRF1 (0.43) KDM4ELMNARAB9ANPC1CTSA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof PAYNE LINDA S (US) 2003-12-11 US claimed
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof PAYNE LINDA S (US) 2003-12-11 US disclosed
EP-1196384-A4 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO INC (US) 2002-10-23 EP disclosed
EP-1196384-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF Merck & Co., Inc. (US) 2002-04-17 EP disclosed
WO-2001000578-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO., INC. (US) 2001-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof CYP2S1, IMPDH1, IDO1 KDM4E 1768/4885NPSR1 4523/4885LMNA 3637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.